Skip to main content

Table 3 Indirect comparisons calculated from the consistency equation

From: Comparison of anti-malarial drug efficacy in the treatment of uncomplicated malaria in African children and adults using network meta-analysis

Ref

Plac

Study per comparison

Parameters

Consistency OR

Model 2 95% CI

Inconsistency OR

Model 3 95% CI

ASMQ

AQSP

2

\(d_{27} = d_{17} - d_{12}\)

0.63

0.26–1.52

0.67

0.22–1.97

DHAPa

AQSP

3

\(d_{2,12} = d_{1,12} - d_{12}\)

2.20

1.21–3.96

1.96

0.89–4.30

ASSP

AQSP

3

\(d_{2,11} = d_{1,11} - d_{12}\)

1.55

0.76–3.21

1.03

0.26–4.15

ASAQCPH

ASAQ

1

\(d_{34} = d_{14} - d_{13}\)

1.38

0.26–7.41

1.75

0.23–8.69

ASMQ

ASAQ

1

\(d_{37} = d_{17} - d_{13}\)

1.07

0.47–2.44

1.15

0.44–3.00

ASSMP

ASAQ

2

\(d_{3,10} = d_{1,10} - d_{13}\)

1.03

0.42–2.51

1.51

0.46–5.01

ASCD

ASAQ

2

\(d_{36} = d_{16} - d_{13}\)

0.52

0.23–1.15

0.69

0.25–1.94

ASSP

ASAQ

7

\(d_{3,11} = d_{1,11} - d_{13}\)

1.21

0.64–2.27

0.90

0.24–3.41

AQSP

ASAQ

4

\(d_{32} = d_{12} - d_{13}\)

0.78

0.41–1.46

0.87

0.38–2.04

DHAPa

ASAQ

6

\(d_{3,12} = d_{1,12} - d_{13}\)

1.70

1.10–2.64

1.72

1.01–3.07

DHAP

ASCD

1

\(d_{6,12} = d_{1,12} - d_{16}\)

3.25

1.46–7.25

3.17

1.21–8.23

ASSP

ASCD

1

\(d_{6,11} = d_{1,11} - d_{16}\)

2.31

0.95–5.61

2.49

0.78–7.86

DHAP

ASMQ

0

\(d_{7,12} = d_{1,12} - d_{17}\)

1.59

0.62–4.02

1.45

0.50–4.38

DHAP

ASPY

0

\(d_{9,12} = d_{1,12} - d_{19}\)

1.36

0.38–4.87

1.33

0.33–5.35

ASATPG

AL

0

\(d_{15} = d_{35} - d_{13}\)

3.40

0.42–27.31

3.10

0.36–26.62

  1. The third column is the observed number of trials for each comparison. 0 comparison means the trial does not exist in the data set but with A one can estimate the treatment difference. \(d_{kl} = d_{bl} - d_{bk}\) is the consistency equation used to derive all indirect comparisons
  2. Ref reference group, Plac denotes the comparator. OR odds ratio is the overall effect estimated from the entire network, CI confidence interval
  3. aMeans the differences are significant. There was not enough evidence to support the higher efficacy of DHAP compared to ASMQ and ASPY, and there were insufficient data to compare ASATPG to AL. For loops having at least 3 treatments, the variance between treatments effects accounted for the correlation (equals to 0.5) between any pairwise contrasts. DHAP was more efficacious than AQSP and ASAQ